Your browser doesn't support javascript.
loading
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.
Tolaney, Sara M; Goel, Shom; Nadal, Jorge; Denys, Hannelore; Borrego, Manuel R; Litchfield, Lacey M; Liu, Jiangang; Appiah, Adams K; Chen, Yanyun; André, Fabrice.
Affiliation
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Goel S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Nadal J; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Denys H; Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Borrego MR; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
  • Litchfield LM; Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
  • Liu J; Eli Lilly and Company, Indianapolis, Indiana.
  • Appiah AK; Eli Lilly and Company, Indianapolis, Indiana.
  • Chen Y; Eli Lilly and Company, Indianapolis, Indiana.
  • André F; Eli Lilly and Company, Indianapolis, Indiana.
Clin Cancer Res ; 30(1): 39-49, 2024 01 05.
Article in En | MEDLINE | ID: mdl-37906649
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Type: Article